UNSPSC 51111649: Peldesine

This classification denotes a purine nucleoside phosphorylase inhibitor with the molecular formula C12H11N5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7B646RJ70F, chemically known as 4h-pyrrolo(3,2-d)pyrimidin-4-one, 2-amino-3,5-dihydro-7-(3-pyridinylmethyl)- but generally known as peldesine, which bears US NIH Compound Identifier 60817. European Medicines Agency schedules Peldesine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09649MIG.

UNSPSC 51111649 Peldesine, a Commodity code, represents pharmaceutical products that state and local governments procure through health and human services agencies, typically as part of Medicaid, employee health plans, and public health programs. The code covers specific pharmaceutical formulations acquired for distribution through state pharmacy benefit programs, employee group health plans, and related health-care delivery systems. State and local governments buy peldesine through health departments, Medicaid agencies, and related health-benefit administrators that manage prescription programs for eligible populations and state employees.

Texas Health and Human Services Commission posted RFI No. HHS0017013 on April 3, 2026, seeking vendor capabilities and market intelligence for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program designed to establish direct relationships between the state's pharmacy benefit program and pharmaceutical manufacturers. The RFI, which closed April 3, 2026, requests detailed vendor responses regarding capacity to enter direct contracts with self-insured employee group health plans and state agencies outside existing arrangements with pharmacy benefit managers, group purchasing organizations, and wholesalers. Key qualifications solicited include vendors' experience with direct contracting for self-insured employers and health plans in both private and government sectors within the past two years, flexibility to negotiate contracts based on negotiated net pricing models without rebates, and capability to implement value-based or outcomes-based agreements. This RFI functions as a preliminary information-gathering phase to inform the state's future procurement strategy and contracting approach before issuing a formal RFP; no award values, budget ranges, or set-aside designations are identified at this stage.